Loading clinical trials...

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) | Clinical Trials | Clareo Health

Active Not RecruitingPhase 2

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP in Participants With DLBCL (waveLINE)

NCT05406401•Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Lymphoma, Large B-Cell, Diffuse (DLBCL)

Interventions

Zilovertamab Vedotin

Cyclophosphamide

+5 more

Locations

22

Canada

Locations (22)

BC Cancer Victoria-Clinical Trials Unit ( Site 0105)

Victoria, British Columbia, Canada

William Osler Health System ( Site 0106)

Toronto, Ontario, Canada

Hopital du Sacre-Coeur de Montreal ( Site 0108)

Montreal, Quebec, Canada

Hadassah Medical Center ( Site 0401)

Jerusalem, Israel

Sheba Medical Center-Hemato Oncology ( Site 0400)

Ramat Gan, Israel

Fondazione Policlinico Universitario Agostino Gemelli-ISTITUTO DI EMATOLOGIA ( Site 0306)

Rome, Lazio, Italy

Key Dates

Start Date

July 14, 2022

Primary Completion Date

April 26, 2029

Completion Date

April 26, 2029

Last Updated

October 15, 2024

Related Studies

RECRUITINGPhase 1

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

NCT06528301

Lymphoma, B-CellLymphoma, Non-Hodgkin (NHL)+2 more

NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy

NCT02544724

Lymphoma, Large B-Cell, Diffuse (DLBCL)

Sponsors

Lead Sponsor

Merck Sharp & Dohme LLC

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 15, 2024Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions